Climb Bio Inc
CLYM
Company Profile
Business description
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Contact
20 William Street
Suite 145
Wellesley HillsMA02481
USAT: +1 866 857-2596
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.40 | 36.90 | -0.41% |
| CAC 40 | 8,082.27 | 0.00 | 0.00% |
| DAX 40 | 24,456.26 | 319.45 | 1.32% |
| Dow JONES (US) | 50,063.46 | 370.26 | 0.75% |
| FTSE 100 | 10,372.93 | 47.58 | 0.46% |
| HKSE | 26,155.33 | 233.71 | -0.89% |
| NASDAQ | 26,635.22 | 232.88 | 0.88% |
| Nikkei 225 | 62,141.93 | 512.12 | -0.82% |
| NZX 50 Index | 12,951.78 | 73.29 | -0.56% |
| S&P 500 | 7,501.24 | 56.99 | 0.77% |
| S&P/ASX 200 | 8,637.50 | 36.00 | -0.42% |
| SSE Composite Index | 4,144.33 | 33.58 | -0.80% |